Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ION775 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| ION775: Cohort A | EXPERIMENTAL | Participants will be randomized to receive ION775 by subcutaneous (SC) injection. |
| ION775: Cohort B | EXPERIMENTAL | Participants will be randomized to receive ION775 by SC injection. |
| ION775: Cohort C | EXPERIMENTAL | Participants will be randomized to receive ION775 by SC injection. |
| Name | Type | Description |
|---|---|---|
| ION775 | DRUG | ION775 will be administered by SC injection. |
Key Inclusion Criteria: 1. Adult males and females with HTG (fasting TG more than or equal to (≥) 350 milligrams per deciliter (mg/dL) \[3.95 millimoles per liter (mmol/L)\] or with sHTG (fasting TG ≥ 500 mg/dL \[5.65 mmol/L\]). 2. Participants should be on standard of care lipid-lowering medicatio...
ION775 is an investigational drug being developed for the treatment of hypertriglyceridemia, including severe hypertriglyceridemia. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
ION775 targets APOC3, a protein involved in triglyceride metabolism. By targeting APOC3, the drug aims to reduce triglyceride levels in patients with hypertriglyceridemia.
ION775 is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
ION775 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies and is still undergoing clinical trials to assess its safety and effectiveness.
ION775 is being studied in a Phase 2 clinical trial with the identifier NCT07604974. This trial is recruiting participants with hypertriglyceridemia or severe hypertriglyceridemia in the United States and Canada, with an enrollment target of 72 patients.